carvedilol has been researched along with Obesity in 5 studies
Obesity: A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Catecholamine excess reflecting an adrenergic overdrive of the sympathetic nervous system (SNS) has been proposed to link to hyperleptinemia in obesity and may contribute to the development of metabolic disorders." | 7.91 | Carvedilol improves glucose tolerance and insulin sensitivity in treatment of adrenergic overdrive in high fat diet-induced obesity in mice. ( Baker, S; Dang, TB; Doan, KV; Kim, KW; Le Tran, T; Nguyen, LV; Nguyen, PH; Nguyen, T; Nguyen, TH; Pham, TVH; Ta, QV; Yang, DJ, 2019) |
| "To study efficacy and safety of a preparation of carvedilol Acridilol (Akrikhin, Russia) in patients with mild and moderate arterial hypertension (AH) and obesity and/or compensated type 2 diabetes mellitus (DM)." | 5.13 | [First results of open randomized clinical study of Acridilol in combination therapy of patients with arterial hypertension and obesity or type 2 diabetes (Mellitus-Open Multicenter Clinical Study ACCORD)]. ( Deev, AD; Lukina, IuV; Martsevich, SIu; Oganov, RG; Shal'nova, SA, 2008) |
| "40 rats were randomly divided into 4 groups: control, untreated atherosclerosis group, atherosclerotic rats treated with carvedilol (10mg/kg/d) and atherosclerotic rats treated with alendronate sodium (10mg/kg/d)." | 4.02 | Matrix metalloproteinase 9 a potential major player connecting atherosclerosis and osteoporosis in high fat diet fed rats. ( Abdelgwad, M; Estaphan, S; Kamar, S; Mostafa, S; Rashed, L; Sabry, M, 2021) |
| "Catecholamine excess reflecting an adrenergic overdrive of the sympathetic nervous system (SNS) has been proposed to link to hyperleptinemia in obesity and may contribute to the development of metabolic disorders." | 3.91 | Carvedilol improves glucose tolerance and insulin sensitivity in treatment of adrenergic overdrive in high fat diet-induced obesity in mice. ( Baker, S; Dang, TB; Doan, KV; Kim, KW; Le Tran, T; Nguyen, LV; Nguyen, PH; Nguyen, T; Nguyen, TH; Pham, TVH; Ta, QV; Yang, DJ, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 2 (40.00) | 2.80 |
| Authors | Studies |
|---|---|
| Yamamoto, PA | 1 |
| Cristofoletti, R | 1 |
| Vozmediano, V | 1 |
| de Gaitani, CM | 1 |
| da Silva, RM | 1 |
| Kemp, R | 1 |
| Sankarankutty, AK | 1 |
| Salgado Junior, W | 1 |
| Santos, JSD | 1 |
| de Moraes, NV | 1 |
| Nguyen, LV | 1 |
| Ta, QV | 1 |
| Dang, TB | 1 |
| Nguyen, PH | 1 |
| Nguyen, T | 1 |
| Pham, TVH | 1 |
| Nguyen, TH | 1 |
| Baker, S | 1 |
| Le Tran, T | 1 |
| Yang, DJ | 1 |
| Kim, KW | 1 |
| Doan, KV | 1 |
| Sabry, M | 1 |
| Mostafa, S | 1 |
| Rashed, L | 1 |
| Abdelgwad, M | 1 |
| Kamar, S | 1 |
| Estaphan, S | 1 |
| Wang, Q | 1 |
| Liu, Y | 1 |
| Fu, Q | 1 |
| Xu, B | 1 |
| Zhang, Y | 1 |
| Kim, S | 1 |
| Tan, R | 1 |
| Barbagallo, F | 1 |
| West, T | 1 |
| Anderson, E | 1 |
| Wei, W | 1 |
| Abel, ED | 1 |
| Xiang, YK | 1 |
| Shal'nova, SA | 1 |
| Martsevich, SIu | 1 |
| Deev, AD | 1 |
| Lukina, IuV | 1 |
| Oganov, RG | 1 |
1 trial available for carvedilol and Obesity
| Article | Year |
|---|---|
[First results of open randomized clinical study of Acridilol in combination therapy of patients with arterial hypertension and obesity or type 2 diabetes (Mellitus-Open Multicenter Clinical Study ACCORD)].
Topics: Adrenergic alpha-Antagonists; Adult; Angiotensin-Converting Enzyme Inhibitors; Carbazoles; Carvedilo | 2008 |
4 other studies available for carvedilol and Obesity
| Article | Year |
|---|---|
Effect of Roux-En-Y Gastric Bypass in the Pharmacokinetics of (R)-Carvedilol and (S)-Carvedilol.
Topics: Carvedilol; Comorbidity; Gastric Bypass; Humans; Obesity; Obesity, Morbid | 2023 |
Carvedilol improves glucose tolerance and insulin sensitivity in treatment of adrenergic overdrive in high fat diet-induced obesity in mice.
Topics: Adipose Tissue, White; Administration, Oral; Adrenergic Agents; Adrenergic beta-Antagonists; Animals | 2019 |
Matrix metalloproteinase 9 a potential major player connecting atherosclerosis and osteoporosis in high fat diet fed rats.
Topics: Alendronate; Alkaline Phosphatase; Animals; Atherosclerosis; Biomarkers; Bone Density; Bone Remodeli | 2021 |
Inhibiting Insulin-Mediated β2-Adrenergic Receptor Activation Prevents Diabetes-Associated Cardiac Dysfunction.
Topics: Animals; beta-Arrestin 2; Carbazoles; Carvedilol; Cells, Cultured; Cyclic Nucleotide Phosphodiestera | 2017 |